Expressions of dual specific phosphatase 14 and nuclear receptor interacting protein 1 in triple negative breast cancer and their prognostic value

doi:10.3877/cma.j.issn.1674-0807.2024.04.002

Abstract

Abstract:

Objective

To explore the expression levels of dual specific phosphatase 14 (DUSP14) and nuclear receptor interacting protein 1 (NRIP1) in triple negative breast cancer (TNBC) and their relationship with patients’ prognosis.

Methods

A total of 106 TNBC patients admitted to Fenyang Hospital Affiliated to Shanxi Medical University from May 2018 to March 2020 were selected as the subjects for a retrospective study. Immunohistochemical methods were applied to detect the expression levels of DUSP14 and NRIP1 in TNBC tissues and adjacent normal tissues, and the paired chi-square test was used to analyze the difference. The correlation of DUSP14 and NRIP1 in TNBC tissues was analyzed by the Spearman analysis. The Kaplan-Meier survival analysis and log-rank test were applied to analyze the relationship between the expression of DUSP14 and NRIP1 in TNBC tissues and patients’ prognosis. The COX analysis was applied to find the prognostic factors of TNBC patients.

Results

The positive expression rates of DUSP14 and NRIP1 in cancer tissues of TNBC patients were significantly higher than those in adjacent normal tissues (70.75% vs 12.26%; 76.42% vs 33.96%; both P<0.001). Spearman correlation analysis showed a significant positive correlation between DUSP14 expression and NRIP1 expression in TNBC tissues (r=0.278, P<0.001). The survival analysis showed that the 3-year overall survival rate of DUSP14-positive patients was significantly lower than that of DUSP14-negative patients (37.33% vs 87.10%; χ²=18.165, P<0.001); the 3-year overall survival rate of NRIP1-positive patients was significantly lower than that of NRIP1-negative patients (41.98% vs 84.00%; χ²=11.754, P=0.001). The multivariate COX analysis showed that DUSP14, NRIP1 and TNM stage were affecting factors for the prognosis of TNBC patients (HR=7.736, 10.243, 9.875; 95%CI: 3.739-16.007, 4.845-21.657, 3.620-26.938, all P<0.050).

Conclusion

High expressions of DUSP14 and NRIP1 in cancer tissues of TNBC patients indicate a poor prognosis, so DUSP14 and NRIP1 maybe serve as potential therapeutic targets for TNBC.

Key words: Triple negative breast cancer, Dual specificity phosphatase 14, Nuclear receptor interacting protein 1, Prognosis

Haigang Niu, Wenke Guo. Expressions of dual specific phosphatase 14 and nuclear receptor interacting protein 1 in triple negative breast cancer and their prognostic value[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 199-205.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2024.04.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2024/V18/I04/199

Figures/Tables 12

References 20

[1]	Wilkinson L，Gathani T. Understanding breast cancer as a global health concern[J].Br J Radiol，2022，95(1130)：20211033.
[2]	Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer[J].Annu Rev Pathol，2022，17(1)：181-204.
[3]	Wei Y，Wang G，Wang C, et al. Upregulation of DUSP14 affects proliferation，invasion and metastasis, potentially via epithelial-mesenchymal transition and is associated with poor prognosis in pancreatic cancer[J].Cancer Manag Res，2020，12(1)：2097-2108.
[4]	Aziz MH，Chen X，Zhang Q，et al.Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo[J].Oncotarget，2015，6(37)：39714-39724.
[5]	中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志，2021，31(10)：954-1040.
[6]	张洁，王磊，刘春玲．三阴乳腺癌组织KIAA1522、β-catenin表达变化及其与患者临床病理特征和预后的关系[J].山东医药，2019，59(10)：22-25.
[7]	邹丹，赵爱琴，王晓庆，等．双特异性磷酸酶14、微小RNA-873-3p在宫颈癌组织中的表达及与临床病理特征和预后的关系[J].中国性科学，2022，31(10)：113-117.
[8]	Nielsen TO，Leung SCY，Rimm DL，et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in Breast Cancer Working Group[J].J Natl Cancer Inst，2021，113(7)：808-819.
[9]	《乳腺癌HER2检测指南(2019版)》编写组．乳腺癌HER2检测指南(2019版)[J].中华病理学杂志，2019，48(3)：169-175.
[10]	李秀翠，赵成，邵华，等．乳腺癌组织中Bmi-1、miR-221-3P的表达及意义[J].山东医药，2018，58(41)：22-25.
[11]	张伟强，王凤琴，仝志超，等．乳腺癌患者丝氨酸-苏氨酸激酶受体、癌胚抗原、糖类抗原125、恶性肿瘤特异性生长因子水平及临床意义[J].诊断病理学杂志，2022，29(9)：814-818.
[12]	Pulido R，Lang R．Dual specificity phosphatases：from molecular mechanisms to biological function[J].Int J Mol Sci，2019，20(18)：4372.
[13]	Gao PP，Qi XW，Sun N，et al.The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer[J].Biochim Biophys Acta Rev Cancer，2021，1876(1)：188562.
[14]	程修强，吴景，何杰．双特异性磷酸酶14在胃癌中的表达情况及其临床意义[J].安徽卫生职业技术学院学报，2021，20(1)：92-94.
[15]	邱振东，王卫星．受体相互作用蛋白1在部分消化系统肿瘤中的研究进展[J].腹部外科，2019，32(4)：300-303.
[16]	Binato R，Corrêa S，Panis C，et al.NRIP1 is activated by C-JUN/C-FOS and activates the expression of PGR, ESR1 and CCND1 in luminal A breast cancer[J].Sci Rep，2021，11(1)：21159.
[17]	Flindris S，Katsoulas N，Goussia A，et al. The expression of NRIP1 and LCOR in endometrioid endometrial cancer[J]. In Vivo, 2021, 35(5)：2631-2640.
[18]	张淼，曾超，周秀春，等．LCoR、NRIP1蛋白在宫颈癌组织中的表达及与临床病理、预后的关系分析[J].中国性科学，2022，31(1)：68-71.
[19]	章伟玲，姚涓，陈肖静，等．宫颈癌患者肿瘤组织中ANGPTL4和NRIP1蛋白表达水平及与预后的关系[J].中国妇产科临床杂志，2023，24(1)：9-11.
[20]	Fang D，Lu G．Expression and role of nuclear receptor-interacting protein 1(NRIP1) in stomach adenocarcinoma[J].Ann Transl Med，2020，8(20)：1293-1309.

变量	变量类型	赋值
DUSP14	X₁	阴性＝0；阳性＝1
NRIP1	X₂	阴性＝0；阳性＝1
TNM分期	X₃	Ⅰ、Ⅱ期＝0，Ⅲ期＝1
组织学分级	X₄	1级＝0；2、3级＝1
淋巴结转移	X₅	无＝0；有＝1
组织分化	X₆	中、高分化＝0；低分化＝1
Ki-67	X₇	<20%＝0；≥20%＝1
HER-2	X₈	阴性＝0；阳性＝1
预后	Y	生存＝0；死亡＝1

变量	变量类型	赋值
DUSP14	X₁	阴性＝0；阳性＝1
NRIP1	X₂	阴性＝0；阳性＝1
TNM分期	X₃	Ⅰ、Ⅱ期＝0，Ⅲ期＝1
组织学分级	X₄	1级＝0；2、3级＝1
淋巴结转移	X₅	无＝0；有＝1
组织分化	X₆	中、高分化＝0；低分化＝1
Ki-67	X₇	<20%＝0；≥20%＝1
HER-2	X₈	阴性＝0；阳性＝1
预后	Y	生存＝0；死亡＝1

癌旁正常组织	癌组织		合计
癌旁正常组织	阳性	阴性	合计
阳性	5	8	13
阴性	70	23	93
合计	75	31	106

癌旁正常组织	癌组织		合计
癌旁正常组织	阳性	阴性	合计
阳性	5	8	13
阴性	70	23	93
合计	75	31	106

临床病理特征	例数	DUSP14表达		χ²值	P值	NRIP1表达		χ²值	P值
临床病理特征	例数	阴性(n＝31)	阳性(n＝75)	χ²值	P值	阴性(n＝25)	阳性(n＝81)	χ²值	P值
年龄
<50岁	50	16(32.00)	34(68.00)	0.347	0.556	15(30.00)	35(70.00)	2.161	0.142
≥50岁	56	15(26.79)	41(73.21)	0.347	0.556	10(17.86)	46(82.14)	2.161	0.142
绝经状态
是	38	10(26.32)	28(73.68)	0.246	0.620	12(31.58)	26(68.42)	2.100	0.147
否	68	21(30.88)	47(69.12)	0.246	0.620	13(19.12)	55(80.88)	2.100	0.147
肿瘤直径
≤2 cm	46	17(36.96)	29(63.04)	2.335	0.126	15(32.61)	31(67.39)	3.672	0.055
>2 cm	60	14(23.33)	46(76.67)	2.335	0.126	10(16.67)	50(83.33)	3.672	0.055
病理类型
浸润性小叶癌	70	15(21.43)	55(78.57)	5.136	0.162	13(18.57)	57(81.43)	2.060	0.560
浸润性导管癌	13	7(53.85)	6(46.15)			5(38.46)	8(61.54)
髓样癌	11	5(45.45)	6(54.55)			4(36.36)	7(63.64)
其他	12	4(33.33)	8(66.67)			3(25.00)	9(75.00)
TNM分期
Ⅰ、Ⅱ期	67	12(17.91)	55(82.09)	11.307	0.001	11(16.42)	56(83.58)	5.190	0.023
Ⅲ期	39	19(48.72)	20(51.28)	11.307	0.001	14(35.90)	25(64.10)	5.190	0.023
组织学分级
1级	39	16(41.03)	23(58.97)	4.138	0.042	14(35.90)	25(64.10)	5.190	0.023
2、3级	67	15(22.39)	52(77.61)	4.138	0.042	11(16.42)	56(83.58)	5.190	0.023
淋巴结转移
有	45	3(6.67)	42(93.33)	19.265	<0.001	6(13.33)	39(86.67)	4.560	0.033
无	61	28(45.90)	33(54.10)	19.265	<0.001	19(31.15)	42(68.85)	4.560	0.033
组织分化
低分化	58	12(20.69)	46(79.31)	4.531	0.033	9(15.52)	49(84.48)	4.626	0.031
中、高分化	48	19(39.58)	29(60.42)	4.531	0.033	16(33.33)	32(66.67)	4.626	0.031
Ki-67
≥20%	72	32(44.44)	40(55.56)	13.511	<0.001	33(45.83)	39(54.17)	8.783	0.003
<20%	34	28(82.35)	6(17.65)	13.511	<0.001	26(76.47)	8(23.53)	8.783	0.003
HER-2
阴性	36	6(16.67)	30(83.33)	4.168	0.041	4(11.11)	32(88.89)	4.706	0.030
阳性	70	25(35.71)	45(64.29)	4.168	0.041	21(30.00)	49(70.00)	4.706	0.030

Please choose a citation manager

Content to export